Healthcare
Sensei Biotherapeutics, Inc.(SNSE)
Live Price
Offline$13.00
+20.48% today
1Y Change
+69.71%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- $40.00M
- Revenue Growth
- 0.0%
- EPS Growth
- -1293.3%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sensei Biotherapeutics, Inc. (SNSE) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $13.00 and up 69.7% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -1293.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -1293.3%, free cash flow +17.5% with operating margin 459.5% and ROIC -110.9%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNSE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Above sector median
+459.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -1293.3%, with operating margin around 459.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.0% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.4% | -20.1% | -45.7% |
2026 Mar 30, 2026 | +22.3% | +25.4% | +20.1% | +15.8% |
2025 Nov 14, 2025 | +11.9% | +1.7% | +8.9% | -1.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNSE
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNSE Max Drawdown
-69.23%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNSE and SPY.
Company Overview
Sensei Biotherapeutics, Inc.
NASDAQ Global Market
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
- Leadership
- Christopher W. Gerry
- IPO Date
- Feb 4, 2021
- Employees
- 14
- Street Address
- 451 D Street
- Mailing
- Rockville, MD, 02210
- Region
- Rockville, MD, US
- Reporting Currency
- USD
- Investor Line
- 240 243 8000
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 1.8
Growth
- Revenue
- 0.0%
- EPS
- -1293.3%
- Free Cash Flow
- +17.5%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 459.5%
- Net Margin
- 434.7%
- ROE
- -83.6%
- ROIC
- -110.9%
Balance Sheet
- Debt/Equity
- 0.08
- Current Ratio
- 5.06
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.